Literature DB >> 8613040

Definition of the initial immunologic modifications upon in vitro gliadin challenge in the small intestine of celiac patients.

L Maiuri1, A Picarelli, M Boirivant, S Coletta, M C Mazzilli, M De Vincenzi, M Londei, S Auricchio.   

Abstract

BACKGROUND & AIMS: Mucosal cell-mediated immune response is considered the central event in the pathogenesis of celiac disease. In cultured intestinal explants from celiacs in remission, we have characterized the early stages of gliadin-induced immune activation.
METHODS: Intestinal biopsy specimens (15 treated celiacs and 13 controls) were cultured with gliadin or maize prolamine digests for 24 hours as well as for 1, 2, 4, 6, 8, and 12 hours in some subjects. The expression of immunologic markers was detected by immunocytochemistry.
RESULTS: Gliadin challenge may initiate two parallel pathways, one of which leads to T-cell activation and another that precedes it. Epithelial cells overexpress DR molecules after 1 hour, and in a second stage T lymphocytes become fully activated. Moreover, T lymphocytes migrate in the upper mucosal layers. T lymphocytes that migrate in the higher lamina propria compartments are mainly CD4+ and show markers of activation; migrating intraepithelial lymphocytes are CD8+ and do not express these markers.
CONCLUSIONS: In vitro gliadin challenge is a suitable model to reproduce various immunologic features of celiac lesions; these may be caused by different pathways. The comprehension of these phenomena is essential to clarify the distinctive pathogenic mechanisms leading to disease and may help in defining novel therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8613040     DOI: 10.1053/gast.1996.v110.pm8613040

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  34 in total

1.  Local challenge of oral mucosa with gliadin in patients with coeliac disease.

Authors:  H Lähteenoja; M Mäki; M Viander; A Toivanen; S Syrjänen
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

2.  Getting to grips with gluten.

Authors:  S N McAdam; L M Sollid
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

3.  Immune response of the coeliac nasal mucosa to locally-instilled gliadin.

Authors:  P Torre; S Fusco; F Quaglia; M L La Rotonda; F Paparo; M Maglio; R Troncone; L Greco
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

4.  Immunohistochemical analysis of coeliac mucosa following ingestion of oats.

Authors:  U Srinivasan; E Jones; J Carolan; C Feighery
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

5.  Sourdough bread made from wheat and nontoxic flours and started with selected lactobacilli is tolerated in celiac sprue patients.

Authors:  Raffaella Di Cagno; Maria De Angelis; Salvatore Auricchio; Luigi Greco; Charmaine Clarke; Massimo De Vincenzi; Claudio Giovannini; Massimo D'Archivio; Francesca Landolfo; Giampaolo Parrilli; Fabio Minervini; Elke Arendt; Marco Gobbetti
Journal:  Appl Environ Microbiol       Date:  2004-02       Impact factor: 4.792

6.  The high frequency of coeliac disease and other autoimmune diseases in subjects affected by Type I (insulin-dependent) diabetes mellitus and in their first-degree relatives.

Authors:  L Sabbatella; M Di Tola; A Picarelli
Journal:  Diabetologia       Date:  2002-05       Impact factor: 10.122

Review 7.  Translational mini-review series on the immunogenetics of gut disease: immunogenetics of coeliac disease.

Authors:  P C Dubois; D A van Heel
Journal:  Clin Exp Immunol       Date:  2008-08       Impact factor: 4.330

8.  Cytokine production by intestinal intraepithelial lymphocyte subsets in celiac disease.

Authors:  Francisco León; Laura Sánchez; Cristina Camarero; Garbiñe Roy
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

9.  IL-15 converts human intestinal intraepithelial lymphocytes to CD94 producers of IFN-gamma and IL-10, the latter promoting Fas ligand-mediated cytotoxicity.

Authors:  Ellen C Ebert
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

10.  Gliadin activates mucosal cell mediated immunity in cultured rectal mucosa from coeliac patients and a subset of their siblings.

Authors:  R Troncone; G Mazzarella; N Leone; M Mayer; M De Vincenzi; L Greco; S Auricchio
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.